ArticleAntimicrobial agents and chemotherapy2019
Effects of KPC Variant and Porin Genotype on the
Open access · bronzeAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Systematic Review and Meta-Analysis of Clinical Efficacy and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.International journal of molecular sciences · 2024Pooled it
- In vitro and in vivo antibacterial activity of oral tebipenem in combination with novel β-lactamase inhibitors (avibactam, relebactam, vaborbactam) against KPC-producing Enterobacterales.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Risk factors forMicrobiology spectrum · 2026Article
- Genomic and molecular characterisation of a KPC-producing Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam.BMC genomic data · 2026Article
- Prevalence, Antimicrobial Susceptibility, and Molecular Characteristics of Ceftazidime-Avibactam-ResistantInfection and drug resistance · 2026Article
- Emergence ofbioRxiv : the preprint server for biology · 2025Article
- Identifying drivers of β-lactam/β-lactamase inhibitor resistance emergence and spread before their clinical deployment.medRxiv : the preprint server for health sciences · 2025Article
- Population pharmacokinetics of meropenem-vaborbactam in acutely ill hospitalized patients with various degrees of renal dysfunction including continuous renal replacement therapy.Antimicrobial agents and chemotherapy · 2025Article
- Emergence of KPC-8-producingAntimicrobial agents and chemotherapy · 2025Article
- Meropenem-Vaborbactam for Treatment of Carbapenem-Resistant Enterobacterales: A Narrative Review of Clinical Practice Evidence.Infectious diseases and therapy · 2025Review
- Towards a holistic approach to pulmonary infections. Insights from the Sixth Annual Meeting of Spanish Experts 2024.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Review
- Ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae accompanied hypermucoviscosity acquisition.BMC microbiology · 2024Article
- Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species andAntibiotics (Basel, Switzerland) · 2024Review
- In Vitro Activity of "Old" and "New" Antimicrobials against theAntibiotics (Basel, Switzerland) · 2024Article
- New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Liver Transplantation: Clinical Perspectives, Toxicity, and PK/PD Properties.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory.Antibiotics (Basel, Switzerland) · 2023Review
- Mutations inJAC-antimicrobial resistance · 2023Article
- Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients.Annals of intensive care · 2023Review
- Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates.Antibiotics (Basel, Switzerland) · 2023Review
- The Effectiveness of Imipenem-Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase.Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
William R WilsonDepartment of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Ellen G KlineDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Chelsea E JonesDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Kristin T MorderDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Roberta T MettusDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Yohei DoiDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
M Hong NguyenDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Cornelius J ClancyDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Ryan K ShieldsDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA shieldsrk@upmc.edu.
University of Pittsburgh · US
Funding
Colistin-resistant Acinetobacter baumanniiR01AI104895 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI, ERNST, ROBERT K · 2014 to 2024
$4.2MCaspofungin pharmacokinetics-pharmacodynamics during intra-adbominal candidiasisK08AI114883 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIELDS, RYAN K · 2015 to 2019
$858kEvolution of KPC-K pneumoniae that persist in patients on prolonged antibioticsR21AI111037 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CLANCY, CORNELIUS J · 2015 to 2016
$465kStudy Network of Acinetobacter as a Carbapenem-Resistant Pathogen (SNAP)R21AI135522 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI · 2018 to 2019
$460kChromosomal and plasmid contributions to colistin resistance and virulence in KPC-producing Klebsiella pneumoniaeR21AI128338 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NGUYEN, M. HONG THI · 2017 to 2018
$444kMechanisms and implications of fosfomycin resistance in Escherichia coliR21AI123747 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI · 2016 to 2017
$417kCharacterization and suppression of resistance to new CRE agentsR03AI144636 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIELDS, RYAN K · 2019 to 2020
$157kNIAID NIH HHS K08 AI114883NIAID NIH HHS R01 AI104895NIAID NIH HHS R03 AI144636NIAID NIH HHS R21 AI111037NIAID NIH HHS R21 AI123747NIAID NIH HHS R21 AI128338NIAID NIH HHS R21 AI135522
Abstract
Meropenem-vaborbactam is a new agent with the potential to treat carbapenem-resistant
Indexed as
Anti-Bacterial AgentsAzabicyclo CompoundsBacterial Proteinsbeta-LactamasesBoronic AcidsCarbapenem-Resistant EnterobacteriaceaeCeftazidimeDisk Diffusion Antimicrobial TestsDrug CombinationsEscherichia coliHeterocyclic Compounds, 1-RingHumansKlebsiella pneumoniaeMeropenemPorinsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-lactamase KPC-1beta-LactamasesBoronic AcidsCeftazidimeDrug CombinationsHeterocyclic Compounds, 1-RingMeropenemmeropenem and vaborbactamOmpK36 protein, Klebsiella pneumoniaePorinsceftazidime-avibactamCREdisk diffusiongradient stripKPCmeropenem-vaborbactamporin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.